User:Aivu93/sandbox: Difference between revisions

Content deleted Content added

Inline

Revision as of 18:47, 3 October 2019

Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.^[1]

^ "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. 2007-6. ISSN 1176-6336. PMC 1936307. PMID 18360634. {{cite journal}}: |first= missing |last= (help); Check date values in: |date= (help)

[1] "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. 2007-6. ISSN 1176-6336. PMC 1936307. PMID 18360634. {{cite journal}}: |first= missing |last= (help); Check date values in: |date= (help)

[1]

@@ Line 1: / Line 1: @@
-Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.<ref>{{Cite journal|last=Hutchinson|first=Michael|date=2007-6|title=Natalizumab: A new treatment for relapsing remitting multiple sclerosis|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936307/|journal=Therapeutics and Clinical Risk Management|volume=3|issue=2|pages=259–268|issn=1176-6336|pmc=1936307|pmid=18360634}}</ref>
+Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to α4β1-integrin.<ref>{{Cite journal|first=Michael|date=2007-6|title=Natalizumab: A new treatment for relapsing remitting multiple sclerosis|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936307/|journal=Therapeutics and Clinical Risk Management|volume=3|issue=2|pages=259–268|issn=1176-6336|pmc=1936307|pmid=18360634|via=}}</ref>
-<br />{{dashboard.wikiedu.org sandbox}}
+<br />